Nyxoah Raises EUR15 Million in New Financing, Completes BLAST OSA Clinical Study

Mont-Saint-Guibert, Belgium (ots/PRNewswire) -

Nyxoah S.A., a medical device company focused on the development
and commercialization of a best-in-class hypoglossal nerve
stimulation (HGNS) therapy for the treatment of Obstructive Sleep
Apnea (OSA), announced today that it successfully raised an
additional EUR15 million ($17.1 million USD) in their most recent
round of equity financing.

(Logo: https://mma.prnewswire.com/media/781913/Nyxoah_Logo.jpg )

The financing was led by Cochlear Limited (www.cochlear.com ), an
Australian medical device company (ASX: COH) and global leader in
implantable hearing solutions. Cochlear invested EUR13 million and
the round was completed by several existing Nyxoah shareholders. A
representative of Cochlear has joined the Nyxoah Board.

Robert Taub, Chairman of the Nyxoah Board said: "We are extremely
pleased to welcome Cochlear as a new investor. Their board-level
participation will accelerate Nyxoah's vision of becoming a leader in
OSA therapy."

Jan Janssen, Chief Technology Officer of Cochlear said: "Cochlear
actively monitors the market for novel technologies and implantable
devices that over the long term may leverage its core business.
Nyxoah's minimally invasive solution presents an attractive
alternative for patients with compliance or intolerance issues in
respect of existing therapies. We look forward to working with
Nyxoah."

Nyxoah recently completed the BLAST-OSA (BiLAteral Hypoglossal
Nerve Stimulation for Treatment of Obstructive Sleep Apnea) clinical
study, an essential milestone for its CE marking dossier already
submitted to the European regulatory body.

"Patients from the BLAST OSA study show a major improvement in
sleep apnea symptoms including a significant reduction of ODI (Oxygen
Desaturation Index) and AHI (Apnea Hypopnea Index)," said Enrique
Vega, Chief Executive Officer of Nyxoah S.A. "The Nyxoah therapy was
also associated with high patient compliance and improvements in
patient Quality of Life. We look forward to publishing the clinical
results in a leading medical journal during 2019."

The additional financing will be used to initiate post-CE Mark
European market development activities and to work toward
Investigational Device Exemption (IDE) with the US Food and Drug
Administration (FDA).

About Nyxoah

Nyxoah S.A. is a medical device company focused on the development
of an innovative, neurostimulation-based therapy for patients
suffering from Obstructive Sleep Apnea (OSA). Headquartered in
Mont-Saint-Guibert - Belgium, Nyxoah S.A. was co-founded in 2009 by
Mr. Robert Taub.

Nyxoah has developed the world's first and only battery-free,
leadless and minimally invasive neurostimulator, capable of
delivering bilateral hypoglossal nerve stimulation for moderate to
severe OSA patients who have failed conventional Positive Airway
Pressure (PAP) therapy. For more information, please visit
www.nyxoah.com.

Caution - Investigational device, limited to investigational use.

Related Links: www.nyxoah.com

ots Originaltext: Nyxoah S.A
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Rémi Renard
Remi.renard@nyxoah.com
+32-472-126-440

Original-Content von: Nyxoah S.A, übermittelt durch news aktuell